Quest Diagnostics holds the cleaner structural position, with profitability as the main driver and valuation adding further support. Abbott Laboratories does not offset that deficit through any equally strong structural edge elsewhere. On the market side, Quest Diagnostics is in better shape — its trend is intact while Abbott Laboratories's trend has broken down. That puts structure and market broadly in agreement — Quest Diagnostics's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the S&P 500 universe, making them directly comparable.
This is not just a one-metric split: both profitability and valuation materially support the lead. Quest Diagnostics Incorporated leads by 22 points on the overall comparison score.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
The pair sits on a clearly comparable long-term path, though it is not a near-twin match.
The match is driven mainly by margin consistency and capital structure.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
Quest Diagnostics Incorporated looks stronger on relative valuation, while the broader price setup remains mixed.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where ABT and DGX each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Return on equity adds support too, with a 4-point advantage.
Absolute pricing gives the lead a second hard layer of support, with a trailing P/E that is 11.1 turns lower.
Profitability is the clearest driver, and valuation also supports Quest Diagnostics Incorporated's broader structural position.
Break down the ABT vs DGX comparison across all dimensions with the full interactive tool.
Explore how ABT and DGX each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.